Skip to main content
OpenTrials
Completed

NCT Number: NCT01484340

A Smoking Cessation Trial in HIV-infected Patients in South Africa

The purpose of this study is to conduct a randomized controlled trial (RCT) of intensive anti-smoking counseling plus nicotine replacement therapy versus intensive anti-smoking counseling alone among HIV-infected patients in South Africa, and to concurrently measure the prevalence of smoking among HIV-infected patients in South Africa.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Grace Mokhomo Community Health Center, Klerksdorp, North West, South Africa

Loading trial locations.

About this study

Tobacco use is estimated to be responsible for over 5 million deaths globally every year and HIV/AIDS kills 2 million worldwide, with persons living in the developing world especially at risk. However, the association between tobacco use and HIV is not clearly understood. The introduction of highly active antiretroviral therapy (HAART) has led to longer duration of survival following HIV-infection in the developed world, and now that HAART is being rolled out in the developing world, survival will increase in these highly endemic regions as well. Given this increase in survival, more people will die of non-HIV related illnesses for which smoking plays an important causal role. Smoking cessation for HIV-infected persons has been studied in the US though these studies have had small numbers and limited follow-up. US based studies suggest that approaches that combine nicotine replacement therapy (NRT) and counseling interventions are most successful. Optimal approaches in resource-limited settings have not been determined.

This study will compare intensive counseling plus NRT versus intensive counseling only, comparing smoking cessation at 2, 6 and 12 months. At 6 months, patients who are still current smokers will be given a second opportunity to receive their group assigned intervention, either intensive counseling plus NRT or intensive counseling alone. We will relate smoking exposure and cessation to HIV progression as measured by immunologic and viral markers, risk of respiratory infections, including tuberculosis, and AIDS-related malignancies. The RCT will be performed at the Tshepong HIV Wellness Clinic in Klerksdorp, South Africa, associated with the Reproductive Health & HIV Research Unit of the University of the Witwatersrand, South Africa.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Current, daily smoker (biochemically verified via a positive result on the SmokeScreen® test from GFC Diagnostics Ltd., as described in the outcomes)
  • Be willing to set a quit date within 2 weeks after baseline assessment
  • Agree to participate in study and anticipated to be attending Tshepong Wellness Clinic, Jouberton Community Health Center, or Grace Mokhomo Community Health Center (due to HIV infection) for at least 6 months

Exclusion criteria

  • Pregnant or nursing
  • Currently using smokeless tobacco (including electronic cigarettes, NRT or other cessation treatment)
  • Tuberculosis confirmed case
  • Weight <45 kg or BMI <20
  • Suffering from any unstable medical condition which could preclude use of the nicotine patch:
  • unstable angina
  • uncontrolled hypertension
  • active skin disease (e.g. psoriasis)
  • history of skin allergy

Treatment and study plan

nicotine

Drug

The nicotine patch be given in three phases:

  • 2 weeks of patches at enrollment
  • 6 weeks of patches at two-week follow-up visit
  • 2 weeks of patches at two-month follow-up visit

This schedule will cover the entire 10-week course of therapy as per label instructions: 6 weeks at 21mg; 2 weeks at 14mg; and 2 weeks at 7mg.

Other names: Nicorette

Intensive Counseling

Behavioral

The advice to quit smoking message will follow NCI's 5A's model for smoking cessation counseling. This is a simple smoking cessation counseling strategy with 5 discrete components: (1) Ask about smoking at every opportunity; (2) Advise the patient to quit smoking; (3) Assess readiness to quit; (4) Assist the patient in quitting; and (5) Arrange follow-up.

Visit schedule:

  • Baseline
  • 2-week follow-up (Quit Day)
  • 1-month follow-up
  • 2-month follow-up
  • 3-month follow-up
  • 6-month follow-up

Participants abstinent at 6-month follow-up will be next seen at 12-month follow-up.

Participants still smoking at 6-month follow-up will be offered group-assigned intervention again.

Primary outcomes

  1. Smoking Status Using a Point of Care Test for Measuring Carbon Monoxide (CO)

    Time frame: 6 months from baseline

    A point of care test for measuring carbon monoxide (CO) will be conducted via the piCO Smokerlyzer from OPS Medical, designed specifically for smoking cessation programs and tobacco control programs. Carbon monoxide will be measured in an exhaled breath in parts-per-million (ppm). A reading of ≤ 7ppm will indicate abstinence.

  2. Smoking Status Using a Point of Care Test for Measuring Cotinine

    Time frame: 6 months from baseline

    A point of care urine test for measuring cotinine will also be conducted via the SmokeScreen® test from GFC Diagnostics Ltd. to verify smoking status. A reading of < 0.4 μg/ml cotinine equivalent will indicate abstinence.

Secondary outcomes

  1. Smoking Status (COppm)

    Time frame: 2 months from baseline

    A point of care test for measuring CO will be conducted via the piCO Smokerlyzer from OPS Medical, designed specifically for smoking cessation programs and tobacco control programs. Carbon monoxide will be measured in an exhaled breath in parts-per-million (ppm). A reading of ≤ 7ppm will indicate abstinence.

  2. Smoking Status (COppm)

    Time frame: 12 months from baseline

    A point of care test for measuring CO will be conducted via the piCO Smokerlyzer from OPS Medical, designed specifically for smoking cessation programs and tobacco control programs. Carbon monoxide will be measured in an exhaled breath in parts-per-million (ppm). A reading of ≤ 7ppm will indicate abstinence.

Sponsors and collaborators

Lead sponsor

Johns Hopkins University

Other

Collaborators

  • National Institute on Drug Abuse (NIDA)
  • Truth Initiative
  • University of Witwatersrand, South Africa

Registry information

Acronym: JHU

Important dates

Study start
2014
Primary completion
2016
Study completion
2017
First posted
Dec 2, 2011
Registry last updated
Oct 4, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.